Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Mustang Bio, Inc. (NASDAQ:MBIO) was the target of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 681,000 shares, a decline of 70.8% from the May 31st total of 2,330,000 shares. Currently, 3.0% of the shares of the company are short sold. Based on an average daily trading volume, of 27,180,000 shares, the short-interest ratio is presently 0.0 days.

Mustang Bio Stock Up 4.9 %

Shares of NASDAQ:MBIO traded up $0.02 during midday trading on Thursday, hitting $0.47. The stock had a trading volume of 18,850,882 shares, compared to its average volume of 14,629,253. The company’s 50-day moving average price is $0.31 and its 200-day moving average price is $0.89. The company has a market capitalization of $5.83 million, a P/E ratio of -0.11 and a beta of 1.71. Mustang Bio has a fifty-two week low of $0.13 and a fifty-two week high of $6.46.

Mustang Bio (NASDAQ:MBIO) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.46) earnings per share (EPS) for the quarter. Research analysts expect that Mustang Bio will post -1.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright dropped their price objective on shares of Mustang Bio from $25.00 to $2.00 and set a “buy” rating for the company in a research note on Monday, May 13th.

Institutional Investors Weigh In On Mustang Bio

A hedge fund recently bought a new stake in Mustang Bio stock. Virtu Financial LLC acquired a new stake in Mustang Bio, Inc. (NASDAQ:MBIO) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 30,176 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.29% of Mustang Bio as of its most recent filing with the SEC. 9.95% of the stock is owned by institutional investors and hedge funds.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.